1
|
Li T, Liu Y, Bao W, Luo J, Gao L, Chen X, Wang S, Yu J, Ge Y, Zhang B, Xie N, Xie Z, Chen T, Zhang H. Synergistic Photothermal and Chemical Therapy by Smart Dual‐Functional Graphdiyne Nanosheets for Treatment of Parkinson's Disease. ADVANCED THERAPEUTICS 2021. [DOI: 10.1002/adtp.202100082] [Citation(s) in RCA: 10] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
Affiliation(s)
- Tianzhong Li
- International Collaborative Laboratory of 2D Materials for Optoelectronics Science and Technology of Ministry of Education Institute of Microscale Optoelectronics College of Physics and Optoelectronic Engineering and Otolaryngology Department and Biobank of the First Affiliated Hospital, Shenzhen Second People's Hospital, Health Science Center Shenzhen University 3688 Nanhai Avenue, Nanshan District Shenzhen 518060 China
- Shenzhen International Institute for Biomedical Research 3/F, Building 1‐B, Silver Star Hi‐tech Industrial Park, Longhua District Shenzhen 518110 China
| | - Yao Liu
- Science and Technology Innovation Center Guangzhou University of Chinese Medicine No. 12, Airport Road, Baiyun District Guangzhou 510405 China
| | - Wenli Bao
- International Collaborative Laboratory of 2D Materials for Optoelectronics Science and Technology of Ministry of Education Institute of Microscale Optoelectronics College of Physics and Optoelectronic Engineering and Otolaryngology Department and Biobank of the First Affiliated Hospital, Shenzhen Second People's Hospital, Health Science Center Shenzhen University 3688 Nanhai Avenue, Nanshan District Shenzhen 518060 China
| | - Jingshan Luo
- Science and Technology Innovation Center Guangzhou University of Chinese Medicine No. 12, Airport Road, Baiyun District Guangzhou 510405 China
| | - Lingfeng Gao
- International Collaborative Laboratory of 2D Materials for Optoelectronics Science and Technology of Ministry of Education Institute of Microscale Optoelectronics College of Physics and Optoelectronic Engineering and Otolaryngology Department and Biobank of the First Affiliated Hospital, Shenzhen Second People's Hospital, Health Science Center Shenzhen University 3688 Nanhai Avenue, Nanshan District Shenzhen 518060 China
| | - Xiaojia Chen
- State Key Laboratory of Quality Research in Chinese Medicine Institute of Chinese Medical Sciences University of Macau Avenida da Universidade Taipa China Macau Macau 999078 China
| | - Shengpeng Wang
- State Key Laboratory of Quality Research in Chinese Medicine Institute of Chinese Medical Sciences University of Macau Avenida da Universidade Taipa China Macau Macau 999078 China
| | - Jiangtian Yu
- Shenzhen International Institute for Biomedical Research 3/F, Building 1‐B, Silver Star Hi‐tech Industrial Park, Longhua District Shenzhen 518110 China
| | - Yanqi Ge
- International Collaborative Laboratory of 2D Materials for Optoelectronics Science and Technology of Ministry of Education Institute of Microscale Optoelectronics College of Physics and Optoelectronic Engineering and Otolaryngology Department and Biobank of the First Affiliated Hospital, Shenzhen Second People's Hospital, Health Science Center Shenzhen University 3688 Nanhai Avenue, Nanshan District Shenzhen 518060 China
| | - Bin Zhang
- International Collaborative Laboratory of 2D Materials for Optoelectronics Science and Technology of Ministry of Education Institute of Microscale Optoelectronics College of Physics and Optoelectronic Engineering and Otolaryngology Department and Biobank of the First Affiliated Hospital, Shenzhen Second People's Hospital, Health Science Center Shenzhen University 3688 Nanhai Avenue, Nanshan District Shenzhen 518060 China
| | - Ni Xie
- International Collaborative Laboratory of 2D Materials for Optoelectronics Science and Technology of Ministry of Education Institute of Microscale Optoelectronics College of Physics and Optoelectronic Engineering and Otolaryngology Department and Biobank of the First Affiliated Hospital, Shenzhen Second People's Hospital, Health Science Center Shenzhen University 3688 Nanhai Avenue, Nanshan District Shenzhen 518060 China
| | - Zhongjian Xie
- Shenzhen International Institute for Biomedical Research 3/F, Building 1‐B, Silver Star Hi‐tech Industrial Park, Longhua District Shenzhen 518110 China
| | - Tongkai Chen
- Science and Technology Innovation Center Guangzhou University of Chinese Medicine No. 12, Airport Road, Baiyun District Guangzhou 510405 China
| | - Han Zhang
- International Collaborative Laboratory of 2D Materials for Optoelectronics Science and Technology of Ministry of Education Institute of Microscale Optoelectronics College of Physics and Optoelectronic Engineering and Otolaryngology Department and Biobank of the First Affiliated Hospital, Shenzhen Second People's Hospital, Health Science Center Shenzhen University 3688 Nanhai Avenue, Nanshan District Shenzhen 518060 China
| |
Collapse
|
2
|
Schofield CL, Rodrigo-Navarro A, Dalby MJ, Van Agtmael T, Salmeron-Sanchez M. Biochemical‐ and Biophysical‐Induced Barriergenesis in the Blood–Brain Barrier: A Review of Barriergenic Factors for Use in In Vitro Models. ADVANCED NANOBIOMED RESEARCH 2021. [DOI: 10.1002/anbr.202000068] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022] Open
Affiliation(s)
| | | | - Matthew J. Dalby
- Centre for the Cellular Microenvironment University of Glasgow Glasgow UK
| | - Tom Van Agtmael
- Institute of Cardiovascular and Medical Sciences University of Glasgow Glasgow UK
| | | |
Collapse
|
3
|
Lalatsa A, Schatzlein AG, Uchegbu IF. Strategies to deliver peptide drugs to the brain. Mol Pharm 2014; 11:1081-93. [PMID: 24601686 DOI: 10.1021/mp400680d] [Citation(s) in RCA: 93] [Impact Index Per Article: 9.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022]
Abstract
Neurological diseases such as neurodegeneration, pain, psychiatric disorders, stroke, and brain cancers would greatly benefit from the use of highly potent and specific peptide pharmaceuticals. Peptides are especially desirable because of their low inherent toxicity. The presence of the blood brain barrier (BBB), their short duration of action, and their need for parenteral administration limits their clinical use. However, over the past decade there have been significant advances in delivering peptides to the central nervous system. Angiopep peptides developed by Angiochem (Montreal, Canada), transferrin antibodies developed by ArmaGen (Santa Monica, USA), and cell penetrating peptides have all shown promise in delivering therapeutic peptides across the BBB after intravenous administration. Noninvasive methods of delivering peptides to the brain include the use of chitosan amphiphile nanoparticles for oral delivery and nose to brain strategies. The uptake of the chitosan amphiphile nanoparticles by the gastrointestinal epithelium is important for oral peptide delivery. Finally protecting peptides from plasma degradation is integral to the success of most of these peptide delivery strategies.
Collapse
Affiliation(s)
- Aikaterini Lalatsa
- Department of Pharmaceutics, School of Pharmacy and Biomedical Sciences, University of Portsmouth , St Michael's Building 5.05, White Swan Road, Portsmouth, PO1 2DT, U.K
| | | | | |
Collapse
|
4
|
Abstract
The peptide therapeutic market is one of the fastest growth areas of the pharmaceutical industry. Although few orally administered peptides are marketed and many are in different phases of clinical development, there is no marketed oral peptide therapeutic used for CNS disorders. The major challenges involved in orally delivering peptides to the brain relate to their enzymatic instability and inability to permeate across physiological barriers. The paucity of therapies for the treatment of brain diseases and the presence of the blood-brain barrier excluding 98% of therapeutic molecules necessitates parenteral administration. Various approaches have been applied to enhance oral peptide bioavailability, but only nanoparticulate strategies were able to deliver orally therapeutic peptides to the brain. Although industry may be reluctant to invest in developing oral peptide nanomedicines, the increasingly unmet clinical need and economic burden associated with brain diseases will fuel the development of the first marketed oral-to-brain peptide therapy.
Collapse
|